LicensingNeurimmune inks $760M deal with AstraZenecaLatest NewsNeurimmune has entered into a collaboration and license agreement with AstraZeneca subsidiary Alexion Pharmaceuticals to commercialise its antibody NI006. Read more 9 January 2022 https://european-biotechnology.com/wp-content/uploads/2024/04/Neurimmune.jpfg.jpeg 620 1200 Thomas Gabrielczyk /wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.png Thomas Gabrielczyk2022-01-09 19:18:002026-07-23 09:41:54Neurimmune inks $760M deal with AstraZeneca